Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says endpoints.news/lilly-intere...
Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, following Lilly's $2.8B AtaiBeckley acquisition.
endpoints.news